Role of Clomiphene Citrate Treatment in Subfertility Due to Polycystic Ovarian Syndrome

Mehvish Javeria; Nida Qayyum; Qurat Ul Ain Hanif; Samar Hussain; Sadia Majeed; Muhammad Azam

Mehvish Javeria Senior Registrar CIMS Multan
Nida Qayyum Classified Derma CMH, Multan
Qurat Ul Ain Hanif Classified Gynae, CMH Quetta
Samar Hussain Assistant Professor, Gynecologist, Rashid Latif Medical College, Lahore
Sadia Majeed Classified Gynecologist, CMH Multan
Muhammad Azam Classified pathology, CMH Multan

Abstract

Objective: To assess the frequency of mature follicle rate as a result of clomiphene citrate treatment in subfertility due to polycystic ovarian syndrome.

Methodology: This descriptive cross-sectional study was conducted at Obstetrics and Gynecology department, CMH (Combined Military Hospital), Multan, for 6 months from 1st March to 1st September 2023. The study comprised of 373 cases aged between 20–40 years reporting infertility for longer than a year, having body mass index <28, and having subfertility owing to PCOS. All study participants were subjected to clomiphene citrate treatment. Each woman continued to receive metformin 500 mg thrice a day. Development of mature follicles was observed utilizing transvaginal ultrasound from 10th day onwards.

Results: Of 373 females the mean age of patients was 32.07±4.22 years. Mean weight of the patients was 59.54 ± 6.05 kg whereas the mean height was 1.61 ± 0.067 m. Mean body mass index (BMI) was 22.92 ± 2.28 kg/m². 203(54.4%) patients had primary while 170 (45.6%) had secondary infertility. 128(34.32%) patients had mature follicles on ultrasonography after receiving clomiphene citrate treatment.

Conclusion: It was concluded that patients receiving clomiphene citrate treatment had acceptable number of mature follicles, thereby likely increasing pregnancy rates in women with PCOS.